Cargando…

Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements

Despite the continuous emergence of multi-drug resistant pathogens, the number of new antimicrobials reaching the market is critically low. Natural product peptides are a rich source of bioactive compounds, and advances in mass spectrometry have achieved unprecedented capabilities for the discovery...

Descripción completa

Detalles Bibliográficos
Autores principales: Parsley, Nicole C., Smythers, Amanda L., Hicks, Leslie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527609/
https://www.ncbi.nlm.nih.gov/pubmed/33042872
http://dx.doi.org/10.3389/fcimb.2020.547177
_version_ 1783589094654214144
author Parsley, Nicole C.
Smythers, Amanda L.
Hicks, Leslie M.
author_facet Parsley, Nicole C.
Smythers, Amanda L.
Hicks, Leslie M.
author_sort Parsley, Nicole C.
collection PubMed
description Despite the continuous emergence of multi-drug resistant pathogens, the number of new antimicrobials reaching the market is critically low. Natural product peptides are a rich source of bioactive compounds, and advances in mass spectrometry have achieved unprecedented capabilities for the discovery and characterization of novel molecular species. However, traditional bioactivity assay formats hinder the discovery and biochemical characterization of natural product antimicrobial peptides (AMPs), necessitating large sample quantities and significant optimization of experimental parameters to achieve accurate/consistent activity measurements. Microfluidic devices offer a promising alternative to bulk assay systems. Herein, a microfluidics-based bioassay was compared to the traditional 96-well plate format in respective commercially-available hardware. Bioactivity in each assay type was compared using a Viola inconspicua peptide library screened against E. coli ATCC 25922. Brightfield microcopy was used to determine bioactivity in microfluidic channels while both common optical and fluorescence-based measurements of cell viability were critically assessed in plate-based assays. Exhibiting some variation in optical density and fluorescence-based measurements, all plate-based assays conferred bioactivity in late eluting V. inconspicua library fractions. However, significant differences in the bioactivity profiles of plate-based and microfluidic assays were found, and may be derived from the materials comprising each assay device or the growth/assay conditions utilized in each format. While new technologies are necessary to overcome the limitations of traditional bioactivity assays, we demonstrate that off-the-shelf implementation of microfluidic devices is non-trivial and significant method development/optimization is required before conventional use can be realized for sensitive and rapid detection of AMPs in natural product matrices.
format Online
Article
Text
id pubmed-7527609
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75276092020-10-09 Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements Parsley, Nicole C. Smythers, Amanda L. Hicks, Leslie M. Front Cell Infect Microbiol Cellular and Infection Microbiology Despite the continuous emergence of multi-drug resistant pathogens, the number of new antimicrobials reaching the market is critically low. Natural product peptides are a rich source of bioactive compounds, and advances in mass spectrometry have achieved unprecedented capabilities for the discovery and characterization of novel molecular species. However, traditional bioactivity assay formats hinder the discovery and biochemical characterization of natural product antimicrobial peptides (AMPs), necessitating large sample quantities and significant optimization of experimental parameters to achieve accurate/consistent activity measurements. Microfluidic devices offer a promising alternative to bulk assay systems. Herein, a microfluidics-based bioassay was compared to the traditional 96-well plate format in respective commercially-available hardware. Bioactivity in each assay type was compared using a Viola inconspicua peptide library screened against E. coli ATCC 25922. Brightfield microcopy was used to determine bioactivity in microfluidic channels while both common optical and fluorescence-based measurements of cell viability were critically assessed in plate-based assays. Exhibiting some variation in optical density and fluorescence-based measurements, all plate-based assays conferred bioactivity in late eluting V. inconspicua library fractions. However, significant differences in the bioactivity profiles of plate-based and microfluidic assays were found, and may be derived from the materials comprising each assay device or the growth/assay conditions utilized in each format. While new technologies are necessary to overcome the limitations of traditional bioactivity assays, we demonstrate that off-the-shelf implementation of microfluidic devices is non-trivial and significant method development/optimization is required before conventional use can be realized for sensitive and rapid detection of AMPs in natural product matrices. Frontiers Media S.A. 2020-09-17 /pmc/articles/PMC7527609/ /pubmed/33042872 http://dx.doi.org/10.3389/fcimb.2020.547177 Text en Copyright © 2020 Parsley, Smythers and Hicks. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Parsley, Nicole C.
Smythers, Amanda L.
Hicks, Leslie M.
Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements
title Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements
title_full Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements
title_fullStr Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements
title_full_unstemmed Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements
title_short Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements
title_sort implementation of microfluidics for antimicrobial susceptibility assays: issues and optimization requirements
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527609/
https://www.ncbi.nlm.nih.gov/pubmed/33042872
http://dx.doi.org/10.3389/fcimb.2020.547177
work_keys_str_mv AT parsleynicolec implementationofmicrofluidicsforantimicrobialsusceptibilityassaysissuesandoptimizationrequirements
AT smythersamandal implementationofmicrofluidicsforantimicrobialsusceptibilityassaysissuesandoptimizationrequirements
AT hickslesliem implementationofmicrofluidicsforantimicrobialsusceptibilityassaysissuesandoptimizationrequirements